Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Cancer Cachexia Overview 9 Therapeutics Development 10 Pipeline Products for Cancer Cachexia - Overview 10 Pipeline Products for Cancer Cachexia - Comparative Analysis 11 Cancer Cachexia - Therapeutics under Development by Companies 12 Cancer Cachexia - Therapeutics under Investigation by Universities/Institutes 14 Cancer Cachexia - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Cancer Cachexia - Products under Development by Companies 18 Cancer Cachexia - Products under Investigation by Universities/Institutes 19 Cancer Cachexia - Companies Involved in Therapeutics Development 20 Acacia Pharma Limited 20 Aeterna Zentaris Inc. 21 Aphios Corporation 22 Atara Biotherapeutics, Inc. 23 Eli Lilly and Company 24 Helsinn Healthcare S.A. 25 Incyte Corporation 26 Lakewood-Amedex Inc 27 Novartis AG 28 Obexia AG 29 PsiOxus Therapeutics Limited 30 RaQualia Pharma Inc. 31 Viking Therapeutics, Inc. 32 Cancer Cachexia - Therapeutics Assessment 33 Assessment by Monotherapy Products 33 Assessment by Combination Products 34 Assessment by Target 35 Assessment by Mechanism of Action 38 Assessment by Route of Administration 41 Assessment by Molecule Type 43 Drug Profiles 45 (formoterol fumarate + megestrol acetate) - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 anamorelin hydrochloride - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 Antibody to Inhibit Parathyroid Hormone Related Protein for Cancer Cachexia - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 Aptamer to Activate Calcineurin A for Genetic Disorders and Musculoskeletal Disorders - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 ATA-842 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 AUSRM-057 - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 bimagrumab - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 DLN-101 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 dronabinol - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 espindolol - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 EXT-400 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 Foxo1-nRNA - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 HM-03 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 landogrozumab - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 macimorelin acetate - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 Monoclonal Antibody to Antagonize TWEAK Receptor for Cachexia - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 OBX-1201 - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 Recombinant Peptide to Inhibit CIDEA for Cancer Cachexia - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 Recombinant Protein to Inhibit Activin A for Osteoporosis and Cancer Cachexia - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 RQ-00433412 - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 ruxolitinib phosphate - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 Small Molecules to Inhibit ATGL for Cancer Cachexia and Type 2 Diabetes - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 Synthetic Peptide to Antagonize Melanocortin Receptor for Cancer Cachexia - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 Synthetic Peptides for Cancer Cachexia - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 tertomotide - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 VK-5211 - Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 Cancer Cachexia - Dormant Projects 92 Cancer Cachexia - Discontinued Products 94 Cancer Cachexia - Product Development Milestones 95 Featured News & Press Releases 95 Jun 01, 2016: Helsinn Group to Present at ASCO Pooled Follow up Efficacy Data Analysis From two Phase III Studies for Anamorelin in Cachectic Patients With Non-small Cell Lung Cancer 95 Feb 23, 2016: Helsinn Announces Publication of Anamorelin ROMANA 1 and ROMANA 2 Phase III Studies in The Lancet Oncology 96 Oct 30, 2014: New Data on Fatigue from ROMANA 1, a Pivotal Phase III Study of Anamorelin in Advanced NSCLC Patients with Cachexia Presented at 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology 98 Mar 04, 2013: PsiOxus Therapeutics Completes Patient Enrollment For Phase II Wasting Disease Therapeutic MT-102 99 Aug 28, 2012: Aeterna Zentaris Recruits First Patient For Phase IIA Trial In Cancer Cachexia With AEZS-130 100 Mar 08, 2012: Michael E. DeBakey Veterans Affairs Medical Center Initiates Phase IIa Trial In Cancer Cachexia With Aeterna Zentaris's Ghrelin Agonist, AEZS-130 100 Dec 08, 2011: PsiOxus Therapeutics To Present Data On MT-102 At Cachexia Conference 101 Dec 06, 2011: Acacia Pharma Announces Positive Results From Phase IIa Cancer Cachexia Study 102 Nov 28, 2011: FDA Grants IND To Investigator At Baylor College Of Medicine For Phase IIa Trial With AEZS-130 In Cancer Cachexia 102 Mar 17, 2011: PsiOxus Therapeutics Initiates Phase II Clinical Study Of Wasting Disease Therapeutic MT-102 103 Dec 16, 2010: Myotec Therapeutics Completes Merger With Hybrid BioSystems To Form PsiOxus Therapeutics 104 Apr 26, 2007: Sapphire Therapeutics, Inc. to Present Results From Anamorelin Phase II Cachexia/Anorexia Studies at American Society of Clinical Oncology and Endocrine Society Annual Meetings in June 105 Dec 15, 2005: Sapphire Therapeutics, Inc.’s Oral Ghrelin Mimetic Shows Potential for Treating Cancer Anorexia/Cachexia 105 Jan 10, 2005: Rejuvenon's RC-1291 Ghrelin Mimetic Receives Fast Track Designation From FDA for Cancer Anorexia/Cachexia 106 Appendix 107 Methodology 107 Coverage 107 Secondary Research 107 Primary Research 107 Expert Panel Validation 107 Contact Us 107 Disclaimer 108

List of Tables Number of Products under Development for Cancer Cachexia, H2 2016 10 Number of Products under Development for Cancer Cachexia - Comparative Analysis, H2 2016 11 Number of Products under Development by Companies, H2 2016 13 Number of Products under Investigation by Universities/Institutes, H2 2016 14 Comparative Analysis by Late Stage Development, H2 2016 15 Comparative Analysis by Clinical Stage Development, H2 2016 16 Comparative Analysis by Early Stage Development, H2 2016 17 Products under Development by Companies, H2 2016 18 Products under Investigation by Universities/Institutes, H2 2016 19 Cancer Cachexia - Pipeline by Acacia Pharma Limited, H2 2016 20 Cancer Cachexia - Pipeline by Aeterna Zentaris Inc., H2 2016 21 Cancer Cachexia - Pipeline by Aphios Corporation, H2 2016 22 Cancer Cachexia - Pipeline by Atara Biotherapeutics, Inc., H2 2016 23 Cancer Cachexia - Pipeline by Eli Lilly and Company, H2 2016 24 Cancer Cachexia - Pipeline by Helsinn Healthcare S.A., H2 2016 25 Cancer Cachexia - Pipeline by Incyte Corporation, H2 2016 26 Cancer Cachexia - Pipeline by Lakewood-Amedex Inc, H2 2016 27 Cancer Cachexia - Pipeline by Novartis AG, H2 2016 28 Cancer Cachexia - Pipeline by Obexia AG, H2 2016 29 Cancer Cachexia - Pipeline by PsiOxus Therapeutics Limited, H2 2016 30 Cancer Cachexia - Pipeline by RaQualia Pharma Inc., H2 2016 31 Cancer Cachexia - Pipeline by Viking Therapeutics, Inc., H2 2016 32 Assessment by Monotherapy Products, H2 2016 33 Assessment by Combination Products, H2 2016 34 Number of Products by Stage and Target, H2 2016 36 Number of Products by Stage and Mechanism of Action, H2 2016 39 Number of Products by Stage and Route of Administration, H2 2016 42 Number of Products by Stage and Molecule Type, H2 2016 44 Cancer Cachexia - Dormant Projects, H2 2016 92 Cancer Cachexia - Dormant Projects (Contd..1), H2 2016 93 Cancer Cachexia - Discontinued Products, H2 2016 94 List of Figures Number of Products under Development for Cancer Cachexia, H2 2016 10 Number of Products under Development for Cancer Cachexia - Comparative Analysis, H2 2016 11 Number of Products under Development by Companies, H2 2016 12 Comparative Analysis by Late Stage Development, H2 2016 15 Comparative Analysis by Clinical Stage Development, H2 2016 16 Comparative Analysis by Early Stage Products, H2 2016 17 Assessment by Monotherapy Products, H2 2016 33 Number of Products by Top 10 Targets, H2 2016 35 Number of Products by Stage and Top 10 Targets, H2 2016 35 Number of Products by Top 10 Mechanism of Actions, H2 2016 38 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 38 Number of Products by Routes of Administration, H2 2016 41 Number of Products by Stage and Routes of Administration, H2 2016 41 Number of Products by Molecule Types, H2 2016 43 Number of Products by Stage and Molecule Types, H2 2016 43

Acacia Pharma Limited Aeterna Zentaris Inc. Aphios Corporation Atara Biotherapeutics, Inc. Eli Lilly and Company Helsinn Healthcare S.A. Incyte Corporation Lakewood-Amedex Inc Novartis AG Obexia AG PsiOxus Therapeutics Limited RaQualia Pharma Inc. Viking Therapeutics, Inc.